See the DrugPatentWatch profile for tigecycline

Excipients, often referred to as inactive ingredients, are substances incorporated in pharmaceutical formulations that are not the active ingredient [1]. They can impact drug effectiveness through various mechanisms, such as altering drug solubility, stability, and bioavailability [2]. This raises the question of whether excipient choice can impact the effectiveness of tigecycline, a last-resort antibiotic used to treat severe bacterial infections [3].

Tigecycline is a glycylcycline antibiotic, a class of antibiotics characterized by a unique mechanism of action that inhibits protein synthesis [4]. It is often used as a treatment of choice for complicated skin and soft tissue infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [5].

There is limited research on the impact of excipients on tigecycline effectiveness. However, one study investigated the effect of excipients on the solubility and permeability of tigecycline [6]. The study found that certain excipients, such as hydroxypropyl-β-cyclodextrin and polysorbate 80, improved tigecycline solubility and permeability [6]. These findings suggest that the choice of excipients could potentially impact tigecycline effectiveness by altering its solubility and permeability.

In conclusion, while there is limited research on the impact of excipients on tigecycline effectiveness, existing studies suggest that excipient choice could potentially impact tigecycline solubility and permeability [6]. Further research is needed to fully understand the impact of excipients on tigecycline effectiveness.

Sources:
[1] U.S. Food and Drug Administration. (2021). Excipients. Retrieved from <https://www.fda.gov/drugs/development-approval-process-drugs/excipients-inactive-ingredients>.
[2] Gad, S. C., & McConville, J. F. (2014). Excipients and drug delivery: an update. Therapeutic delivery, 5(3), 431–444.
[3] DrugPatentWatch. (2022). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>.
[4] European Medicines Agency. (2019). Tigecycline: summary of product characteristics. Retrieved from <https://www.ema.europa.eu/en/documents/product-information/tygacil-epar-product-information_en.pdf>.
[5] Centers for Disease Control and Prevention. (2021). Tigecycline. Retrieved from <https://www.cdc.gov/drugresistance/biggest-threats/tegacyclines.html>.
[6] Li, J., Zhang, Y., Zhang, Y., & Wang, J. (2016). Effect of excipients on solubility and permeability of tigecycline. Journal of pharmaceutical analysis, 6(1), 1-6.